Pathstone Family Office, LLC Gamida Cell Ltd. Transaction History

Pathstone Family Office, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 23, 2023	BUY	$1.73 - $4.29 $18,844 - $46,730	10,893 New	10,893 $19,000
Q2 2022 Aug 15, 2022	SELL	$1.73 - $4.29 $783 - $1,943	-453 Reduced 3.99%	10,893 $19,000
Q1 2022 May 16, 2022	SELL	$2.22 - $4.47 $932 - $1,877	-420 Reduced 3.57%	11,346 $47,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.46 $1,707 - $3,460	776 Added 7.06%	11,766 $30,000
Q3 2021 Nov 16, 2021	BUY	$3.85 - $6.44 $42,311 - $70,775	10,990 New	10,990 $43,000
Q1 2021 May 14, 2021	SELL	$7.8 - $12.43 $35,100 - $55,935	-4,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$4.07 - $11.0 $18,315 - $49,500	4,500 New	4,500 $38,000

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

Stay updated on Pathstone Family Office, LLC with notifications on news.